Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

1082

Figures (1-3)

270

Sum=1479

Publishing Process of This Article

Item

Count

Browse

Download

223

Sum=311

Dec 26, 2022 (publication date) through Jul 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. Dec 26, 2022; 10(36): 13208-13215
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13208

Full Size Figure Download Figure

Figure 2 Comparison of complement levels (g/L) between the hypersplenism group and the control group. ^aP < 0.05; ^bP < 0.001.

Citation: Zhang K, Zeng M, Li YJ, Wu HF, Wu JC, Zhang ZS, Zheng JF, Lv YF. Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles. World J Clin Cases 2022; 10(36): 13208-13215
URL: https://www.wjgnet.com/2307-8960/full/v10/i36/13208.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i36.13208